Silence Therapeutics: New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a)

 Assessment showed participants who received a single dose of SLN360 maintained median reductions over 80% over a five-month period

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today presented data from an analysis of its APOLLO phase 1 single dose study of SLN360, an investigational short interfering ribonucleic acid (“siRNA”), in healthy adults with high lipoprotein(a) (“Lp(a)”), a key genetic risk factor for heart disease, at the American Heart Association (“AHA”) 2022 Annual Meeting.

The moderated poster entitled, “Time Averaged Lipoprotein(a) Reduction with SLN360, A Novel SiRNA Targeting Lp(a) in Healthy Adults with Elevated Lp(a),” assessed Lp(a) levels of participants in the APOLLO single dose study during five months of follow up.

In the top two SLN360 single dose groups (300 mg and 600 mg), median time-averaged Lp(a) reductions over 150 days exceeded 80%. At day 365, some participants still exhibited substantial knockdown of Lp(a) to approximately 50% of baseline. Additionally, extension data to day 365 showed no new drug related safety findings in either dose group.

https://www.marketscreener.com/quote/stock/SILENCE-THERAPEUTICS-PLC-120790933/news/Silence-Therapeutics-Presents-New-Analysis-from-SLN360-Phase-1-Single-Dose-Study-in-High-Lipoprotein-42214896/